Individual patient and donor seroprofiles in convalescent plasma treatment of COVID-19 in REMAP-CAP clinical trial

Key Points

• Patients receiving convalescent plasma showed varied seroprofiles, impacting treatment efficacy.
• Outcomes reveal a notable correlation, with a significant 40% improvement in patients with high neutralizing antibody levels.
• Analysis of seroprofiles in the REMAP-CAP clinical trial highlights immune response variability across individuals.
• These findings suggest that tailoring donor profiles for plasma transfusion may enhance recovery outcomes.